



BETA DRUGS LIMITED

11th October, 2018

The Manager
National Stock Exchange of India Ltd.
Exchange Plaza, C/1, Block G
Bandra - Kurla Complex, Bandra (East)
Mumbai 400 051

NSE Symbol: BETA

Sub: Intimation of Incorporation of a Wholly Owned Subsidiary Company.

With reference to the captioned subject, we would like to inform you that Company has incorporated a wholly owned subsidiary company namely, "Adley Formulations Private Limited" registered with the Registrar of Companies, National Capital Territory of Delhi & Haryana on 9th October, 2018 and intimation received on 10th October, 2018.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD4/2015 dated 9th September, 2015 is given as under:

Sr. No.	Particulars	Details
(a)	Name of the target entity, details in brief such as size, turnover etc.	Adley Formulations Private Limited newly incorporated wholly owned subsidiary. Authorised Share Capital-Rs 1,00,00,000 (Rupees One Crore) Paid up Capital – Rs 1,00,000 (10,000 Equity shares @ Rs 10/-each) Turnover – Nil (Yet to commence Business operation)
(b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	Beta Drugs Limited has incorporated a Wholly Owned Subsidiary. There is no acquisition.
(c)	Industry to which the entity being acquired belongs CIN No.: U24230HP2005PLC028969	Pharmaceutical.

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Export & Mktg Office : 1101, 11th Floor, Peninsula Park, Andheri West, Mumbai - 400053, Phone No. : +91-022-62360443

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com
www.adleylab.com

E-Mail :- info@betadrugslimited.com
sales@adleylab.com


(d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Manufacturing and Trading of Generic Pharmaceuticals and Oncology Products.
(e)	Brief details of any governmental or regulatory approvals required for the acquisition.	No
(f)	Indicative time period for completion of the acquisition	N.A.
(g)	Nature of consideration – whether cash consideration or share swap and details of the same;	Cash
(h)	Cost of acquisition or the price at which the shares are acquired;	Value of Shares Subscribed- Rs 1,00,000 (10,000 Equity shares @ Rs 10/-each)
(i)	Percentage of shareholding / control acquired and / or number of shares acquired;	100%
(j)	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Adley Formulations Private Limited is incorporated in India and registered with the Registrar of Companies, National Capital Territory of Delhi & Haryana on 9 th October, 2018 and is yet to commence its business operations.

Kindly take this on record.

Thanking you.

Yours faithfully,

For Beta Drugs Limited



Rajni Brar

Company Secretary